Minimal residual disease or MRD — defined as a very small number of cancer cells that remain in the body during or after treatment —…
Myeloma
Most people with relapsed or refractory multiple myeloma (RRMM) given the cell therapy anitocabtagene autoleucel — known as anito-cel — in a Phase 2…
The cell therapy Carvykti (ciltacabtagene autoleucel) — approved earlier this year as a second-line treatment for people with multiple myeloma — was shown to delay…
Researchers in Belgium have developed an atlas to mark changes in distinct types of immune cells during multiple myeloma’s  progression. Their work, in…
The U.S. Food and Drug Administration (FDA) will review GSK’s request to approve Blenrep (belantamab mafodotin) as part of a combination treatment for adults…
A combination therapy using Blenrep (belantamab mafodotin) was more effective at extending life in people with relapsed or refractory multiple myeloma than a combo treatment…
A standard autologous hematopoietic stem cell transplant (AHSCT) safely and effectively prolongs survival and delays cancer progression in adults with multiple myeloma, a…
The subcutaneous (under-the-skin) formulation of Darzalex (daratumumab) has been approved in the European Union as part of a combination treatment for adults with newly…
Johnson & Johnson (J&J) is asking regulatory authorities in the European Union to approve a combination treatment based on the subcutaneous, or under-the-skin, formulation…
Real-world treatment with the cell therapy Carvykti (ciltacabtagene autoleucel) was found to be highly effective among people with difficult-to-treat multiple myeloma in a multicenter…
Recent Posts
- Partners to collect real-world data to speed care for kids with AML
- Study finds home transfusions safe in hospice care for blood cancer
- Small acts of defiance are the ways we push back against disease
- Under-the-skin myeloma treatment linked to better survival in study
- Add-on therapy shows promise for hard-to-treat AML